Onconetix, Inc. (ONCO) director discloses zero share ownership as of December 5, 2025

Rhea-AI Filing Summary

Onconetix, Inc. director Sarah Romano filed an initial insider ownership statement reporting that she beneficially owns no company securities as of December 5, 2025.

The filing identifies her as a director, not a 10% owner or officer, and notes that the form is filed by one reporting person. Both the non-derivative and derivative securities tables show no holdings, consistent with the explanation that no securities are beneficially owned.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Romano Sarah

(Last) (First) (Middle)

C/O ONCONETIX, INC.

201 E. FIFTH STREET, SUITE 1900

(Street)

CINCINNATI OH 45202

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/05/2025

3. Issuer Name and Ticker or Trading Symbol
Onconetix, Inc. [ ONCO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Sarah Romano	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Onconetix (ONCO) disclose about director Sarah Romano's holdings?

The company disclosed that director Sarah Romano beneficially owns no securities of Onconetix, Inc., as stated in the explanation of responses.

What is the date of the event for this Onconetix (ONCO) insider ownership filing?

The date of the event requiring the statement is December 5, 2025, as shown in the event date field.

What is Sarah Romano's relationship to Onconetix (ONCO)?

Sarah Romano is identified as a Director of Onconetix, Inc., with the director box checked and no indication that she is a 10% owner or officer.

Does the filing report any non-derivative or derivative securities for Sarah Romano at Onconetix?

No. Both the non-derivative and derivative securities tables are empty, and the explanation of responses states that no securities are beneficially owned.

Is this insider ownership filing for one or multiple reporting persons at Onconetix (ONCO)?

The document indicates that the form is filed by one reporting person, with that option checked in the filing status section.

Under which regulations is this Onconetix insider ownership statement filed?

The statement is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940, as indicated at the top of the form.